SLRX

Salarius Pharmaceuticals Inc

SLRX, USA

Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.

https://www.salariuspharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SLRX
stock
SLRX

Salarius Pharmaceuticals (SLRX) to Rebrand as Decoy Therapeutics GuruFocus

Read more →
SLRX
stock
SLRX

Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$26

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.08

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-20.56 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-14.33 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.44

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.80% of the total shares of Salarius Pharmaceuticals Inc

1.

HRT FINANCIAL LLC

(0.4144%)

since

2025/06/30

2.

UBS Group AG

(0.2373%)

since

2025/06/30

3.

Cubist Systematic Strategies, LLC

(0.2188%)

since

2025/06/30

4.

Goldman Sachs Group Inc

(0.218%)

since

2025/06/30

5.

Geode Capital Management, LLC

(0.2035%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.1223%)

since

2025/07/31

7.

Barclays PLC

(0.105%)

since

2025/06/30

8.

Citigroup Inc

(0.077%)

since

2025/06/30

9.

Fidelity Series Total Market Index

(0.0748%)

since

2025/07/31

10.

Horizon Kinetics Medical ETF

(0.0508%)

since

2025/08/29

11.

Tower Research Capital LLC

(0.0435%)

since

2025/03/31

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0164%)

since

2025/07/31

13.

Fidelity Total Market Index

(0.0042%)

since

2025/07/31

14.

NT Ext Equity Mkt Idx Fd - L

(0.0022%)

since

2025/06/30

15.

Spartan Total Market Index Pool G

(0.0022%)

since

2025/07/31

16.

Northern Trust Extended Eq Market Idx

(0.0022%)

since

2025/06/30

17.

Advisor Group Holdings, Inc.

(0.0021%)

since

2025/03/31

18.

NT Ext Equity Mkt Idx Fd - NL

(0.0019%)

since

2025/06/30

19.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0015%)

since

2025/06/30

20.

Mount Yale Investment Advisors, LLC

(0.0008%)

since

2025/06/30

21.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0006%)

since

2025/06/30

22.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0005%)

since

2024/12/31

23.

Bank of America Corp

(0.0002%)

since

2025/06/30

24.

Morgan Stanley - Brokerage Accounts

(0.0001%)

since

2025/06/30

25.

Northern Trust Wilshire 5000

(0.0001%)

since

2025/06/30

26.

BlackRock Inc

(0%)

since

2025/03/31

27.

SBI Securities Co Ltd

(0%)

since

2025/06/30

28.

Mascagni Wealth Management, Inc.

(0%)

since

2025/03/31

29.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/06/30

30.

Extended Equity Market Fund K

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.8137

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4.5)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.